# An exploratory pharmacokinetics and pharmacodynamics study beta-lactam antibiotics in pediatric intensive care patients: is there a need for more precision?

No registrations found.

**Ethical review** Not applicable

**Status** Pending

Health condition type -

**Study type** Observational non invasive

# **Summary**

#### ID

NL-OMON29496

Source

NTR

**Brief title** 

**EXPAT Kids** 

**Health condition** 

Infectious diseases

# **Sponsors and support**

**Primary sponsor: MRace** 

Source(s) of monetary or material Support: MRace

Intervention

#### **Outcome measures**

## **Primary outcome**

The main objective is to determine the prevalence of target attainment for six frequently used beta-lactam antibiotics in the early phase after start of the therapy in PICU patients. Target attainment for beta-lactam antibiotics is set at 100% of time (T) of the dosing interval in which the unbound (free, f) serum antibiotic concentration remains above the above the epidemiological cut-off (fT > MICECOFF).

#### **Secondary outcome**

To identify risk factors and clinical outcomes associated with target non-attainment. Factors likely to contribute to outcomes are analysed for association based on clinical relevancy and previously described relationship, and include:

- Length of PICU stay, days on antibiotics, microbiological cure, and other clinical outcomes in PICU patients
- Use of other antibiotics
- C-reactive protein (CRP), interleukin 6 (IL-6), and procalcitonin
- Antibiotic resistance development
- Serum albumin
- Estimated glomerular filtration rate (eGFR ≥ 90 mL/min/1.73 m2)
- Presence of continuous renal replacement therapy (CRRT)

# **Study description**

#### **Background summary**

Morbidity and mortality in critically ill patients with infection is a global health problem. Emerging evidence supports the importance of optimized antibiotic exposure in pediatric intensive care unit (PICU) patients, while evidence based antibiotic dosing in PICU patients in clinical practice is limited. Changes in pharmacokinetic (PK) parameters of antibiotics in subpopulations of critically ill patient have been defined in previous studies. However, there are no data from studies assessing whether the issues identified in a controlled research environment correspond to clinical practice. Assessment of pharmacodynamic target attainment is warranted to identify whether clinical outcomes for patients admitted to the PICU can be improved. We propose an exploratory pharmacokinetic and pharmacodynamic (PK/PD) study to analyse whether current antibiotic dosing regimens of frequently used beta lactam antibiotics achieve defined therapeutic target concentrations in PICU patients.

## Study objective

Current antibiotic treatment with beta lactam do not meet pharmacodynamic targets in pediatric intensive care unit patients

## Study design

Day 0 till 6: bioanalysis of bloodsamples for drug exposure (primary)

2 - An exploratory pharmacokinetics and pharmacodynamics study beta-lactam antibioti ... 4-05-2025

# **Contacts**

#### **Public**

Erasmus Medisch Centrum Stef Schouwenburg

010-703320

#### Scientific

Erasmus Medisch Centrum Stef Schouwenburg

010-703320

# **Eligibility criteria**

## **Inclusion criteria**

- Written informed consent has been obtained from the patient or their legally authorised representative
- Suitable intra-arterial access to facilitate sample collection
- Recruitment within 36 hours after start of antibiotic therapy
- Intravenous antibiotic therapy of the target antibiotic should be aimed for at least 2 days

## **Exclusion criteria**

- · Consent not obtained
- Premature infants
- History of anaphylaxis for the study antibiotics
- Study antibiotic cessation before blood collection
- Prophylactic use of the study antibiotics

# Study design

# **Design**

Study type: Observational non invasive

Intervention model: Other

Allocation: Non controlled trial

Masking: Single blinded (masking used)

Control: N/A , unknown

## Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 03-05-2021

Enrollment: 150

Type: Anticipated

## **IPD** sharing statement

Plan to share IPD: No

## **Ethics review**

Not applicable

Application type: Not applicable

# **Study registrations**

# Followed up by the following (possibly more current) registration

No registrations found.

# Other (possibly less up-to-date) registrations in this register

No registrations found.

# In other registers

Register ID

NTR-new NL9326

Other METC EMC : MEC-2021-0173

# **Study results**